Psychiatric symptoms in Parkinson’s disease

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Current Neurology and Neuroscience Reports

• Publication date

  2002-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/S11910-002-0005-6PMID 12044249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacologic Treatment of Tremor

  2008cited by this paper
• Depression in Parkinson's disease: biogenic amines in CSF of “de novo” patients

  2005cited by this paper
• Anxiety and Parkinson’s Disease

  2004cited by this paper
• Non-recognition of depression and other non-motor symptoms in Parkinson's disease.

  2002cited by this paper
• What contributes to depression in Parkinson's disease?

  2001cited by this paper
• Obsessive-compulsive symptoms in Parkinson's disease

  2001cited by this paper
• Quetiapine-Induced Extrapyramidal Side Effects in Patients with Parkinson's Disease: Case Report

  2001cited by this paper
• SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study

  2001cited by this paper
• Prospective study of hallucinations and delusions in Parkinson's disease

  2001cited by this paper
• Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease

  2000cited by this paper
• Clozapine and risperidone treatment of psychosis in Parkinson's disease.

  2000cited by this paper
• Olanzapine and clozapine

  2000cited by this paper
• Gender differences in Parkinson's disease symptom profile

  2000cited by this paper
• Efficacy of quetiapine in Parkinson's patients with psychosis.

  2000cited by this paper
• Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.

  1999cited by this paper
• Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

  1999cited by this paper
• Range of neuropsychiatric disturbances in patients with Parkinson’s disease

  1999cited by this paper
• Parkinson's disease: a preliminary study of yohimbine challenge in patients with anxiety.

  1999cited by this paper
• Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.

  1999cited by this paper
• Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy

  1999cited by this paper
• Classification of fluctuations in patients with Parkinson's disease

  1998cited by this paper
• Depression in classic versus akinetic‐rigid Parkinson's disease

  1998cited by this paper
• Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease.

  1998cited by this paper
• Effectiveness of ECT in patients with parkinsonism.

  1998cited by this paper
• Managing the neuropsychiatric symptoms of Parkinson's disease

  1998cited by this paper
• Early dopaminergic drug-induced hallucinations in parkinsonian patients

  1998cited by this paper
• A survey of antidepressant drug use in Parkinson's disease

  1997cited by this paper
• Anxiety and Parkinson's disease.

  1996cited by this paper
• Visual hallucinations associated with Parkinson disease.

  1996cited by this paper
• Parkinson's disease: drug-induced psychiatric states.

  1995cited by this paper
• Autonomic Failure, Depression and Anxiety in Parkinson's Disease

  1995cited by this paper
• Treatment of depression in Parkinson's disease: a meta-analysis.

  1995cited by this paper
• Depression in Parkinson's disease: a psychosocial viewpoint.

  1995cited by this paper
• Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease

  1995cited by this paper
• Risperidone in Parkinson's disease.

  1994cited by this paper
• Risperidone for hallucinations in levodopa-treated Parkinson's disease patients.

  1994cited by this paper
• Depression in Parkinson's disease.

  1994cited by this paper
• Parkinson's disease and anxiety: comorbidity with depression.

  1993cited by this paper
• Obsessive-compulsive symptoms and motor asymmetries in Parkinson’s disease

  1993cited by this paper
• The involvement of the World Psychiatric Association in the issue of the political abuse of psychiatry

  1993cited by this paper
• A Golgi study of human locus coeruleus in normal brains and in Parkinson's disease

  1993cited by this paper
• “Panic attacks” in Parkinson's disease

  1993cited by this paper
• Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease.

  1992cited by this paper
• Depression and Parkinson's disease: a review.

  1992cited by this paper
• Anxiety disorders in familial parkinsonism.

  1991cited by this paper
• Psychotic complications of long‐term levodopa treatment of Parkinson's disease

  1991cited by this paper
• Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease.

  1990cited by this paper
• Anxiety disorders in patients with Parkinson's disease.

  1990cited by this paper
• Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

  1990cited by this paper
• Depression in Parkinson's Disease

  1990cited by this paper
• Depressive Symptoms in Parkinson's Disease: A Comparison With Disabled Control Subjects

  1990cited by this paper
• Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease

  1990cited by this paper
• Biochemistry of Parkinson's disease 28 years later: A critical review

  1989cited by this paper
• Obsessive-compulsive disorder: evidence for basal ganglia dysfunction.

  1988cited by this paper
• Obsessive-compulsive disorder: evidence for basal ganglia dysfunction.

  1988cited by this paper
• The relationship of serotonin to depression in Parkinson's disease

  1988cited by this paper
• Evidence for atypical depression in Parkinson's disease.

  1988cited by this paper
• The fences of psychiatry.

  1985cited by this paper
• Bupropion in Parkinson's disease

  1984cited by this paper
• Altered serotonin metabolism in depressed patients with Parkinson's disease

  1984cited by this paper
• Levodopa-induced psychosis: a kindling phenomenon.

  1978cited by this paper
• THEORETICAL IMPLICATIONS OF THE USE OF L‐DOPA IN PARKINSONISM.

  1970cited by this paper

• Reduction of tyrosine hydroxylase expression and increase of α-synuclein in the substantia nigra in a rat model of benign prostatic hyperplasia.

  2021cites this paper
• Reformulating Psychological Difficulties in People with Parkinson's Disease: The Potential of a Social Relational Approach to Disablism

  2013influential citation
• Manganese‐enhanced MRI in a rat model of Parkinson's disease

  2007cites this paper
• Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease

  2005cites this paper
• Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson’s disease

  2004cites this paper
• Treatment challenges in early stage Parkinson's disease.

  2004cites this paper